Profile of Hospitalized Hypertensives with Preserved and Reduced Left Ventricular Ejection Fraction in Nigeria

Akinsanya Daniel Olusegun-Joseph, Kamilu M Karaye, Adeseye A Akintunde, Bolanle O Okunowo, Oladimeji G Opadijo, Abdulrazak Garba Habib, Suleiman A Balarabe

Abstract


Introduction

 

The impact of preserved and reduced left ventricular ejection fraction (LVEF) has been well studied in heart failure, but not in hypertension. We aimed to highlight the prevalence, clinical characteristics, comorbidities and outcomes of hospitalized hypertensives with preserved and reduced LVEF from three teaching hospitals in Nigeria.

 

Methods: This is a retrospective study of hypertensives admitted in 2013 in three teaching hospitals in Lagos, Kano and Ogbomosho, who had echocardiography done while on admission. Medical records and echocardiography parameters of the patients were retrieved and analyzed.

 

Results: 54 admitted hypertensive patients who had echocardiography were recruited, of which 30 (55.6%) had reduced left ventricular ejection fraction (RLVEF), defined as ejection fraction <50%; while 24 (44.4%) had preserved left ventricular ejection fraction (PLVEF). There were 37(61.5%) females and 17 (31.5%) males. Of the male patients 64.7% had RLVEF, while 35.3% had PLVEF. 19(51.4%) of females had RLVEF, while 48.6% had PLVEF. Mean age of patients with PLVEF was 58.83±12.09 vs 54.83± 18.78 of RLVEF; p-0.19. Commonest comorbidity was Heart failure (HF) followed by stroke (found among 59.3% and 27.8% of patients respectively). RLVEF was significantly commoner than PLVEF in HF patients (68.8% vs 31.3%; p- 0.019); no significant difference in stroke patients (46.7% vs 53.3%; p-0.44). Mortality occurred in 1 (1.85%) patient who had RLVEF.        

 

Conclusion: RLVEF was more common than PLVEF among admitted hypertensive patients; they also have more comorbidities. In-hospital mortality is, however, very low in both groups.


Keywords


Hypertension, Reduced LV ejection fraction , Preserved LV ejection fraction, Comorbidities, mortality.

Full Text:

PDF

References


REFERENCES

World Health Organization. A global brief on Hypertension. Silent killer, global public health crisis. World Health Day 2013. Geneva, World Health Organization, 2013.

Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva, World Health Organization, 2009.

Lawes CMM, Vander Hoorn S, Rodgers A, for the International Society of Hypertension. Global burden of blood pressure related disease, 2001. Lancet 2008; 371: 1513–1518. DOI: http://dx.doi.org/10.1016/S0140- 6736(08)60655-8.

Lim SS, Vos T, Flaxman AD, Danaei G, et al A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010 : a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380 (9859): 2224-60.

Kenchaiah S, Pfeffer MA. Cardiac remodeling in systemic hypertension. Med Clin North Am. 2004; 88(1):115-30.

Bountioukos M, Schinkel AFL, Bax JJ, MD, Lampropoulos S, Poldermans D. The impact of hypertension on systolic and diastolic left ventricular function. A tissue Doppler echocardiographic study. Am Heart J. 2006;151(6):1323.e7-1323.e1.

Lawler PR, Hiremath P, Cheng S. Cardiac Target Organ Damage in Hypertension: Insights from Epidemiology. Curr Hypertens Rep. 2014 Jul; 16(7): 446. doi: 10.1007/s11906-014-0446-8.

Anguita SM. Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach. Rev Esp Cardiol. 1999;52 Suppl 3:34-8.

Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic Left Ventricular Systolic Dysfunction in Essential Hypertension: Prevalence, Determinants, and Prognostic Value. Hypertension. 2005;45:412-418. https:// doi.org/ 10. 1161/01.HYP.0000154822.37141.f6.

Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002; 137: 631–639.

Yeboah J., Rodriguez C.J., Stacey B., et al. Prognosis of individuals with asymptomatic left ventricular systolic dysfunction in the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2012; 126:2713–2719.

Picard MH, Adams D, Bierig SM, Dent JM, Douglas PS, Gillam LD, Keller AM, Malenka DJ, Masoudi FA etal. American Society of Echocardiography Recommendations for Quality Echocardiography Laboratory Operations. J Am Soc Echocardiogr. 2011 Jan;24(1):1-10. doi: 10.1016/j.echo.2010.11.006.

McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441-6

Dike Ojji, John Atherton, Karen Sliwa, Jacob Alfa, Murtala Ngabea, Lionel Opie; Left Ventricular Systolic Dysfunction in Asymptomatic Black Hypertensive Subjects, American Journal of Hypertension. 2015; 28 (7): 924–929, https://doi.org/10.1093/ajh/hpu247.

Devereux RB, Bella JN, Palmieri V, Oberman A, Kitzman DW, Hopkins PN, Rao DC, Morgan D, Paranicas M, Fishman D, Arnett DK; Hypertension Genetic Epidemiology Network Study Group. Left ventricular systolic dysfunction in a biracial sample of hypertensive adults: The Hypertension Genetic Epidemiology Network (HyperGEN) Study. Hypertension. 2001; 38: 417–423.

Wang TJ, Evans JC, Benjamin EJ, Levy D, Leroy EC, Vasan RS. Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community. Circulation. 2003;108:977-982. doi: 10.1161/01.CIR.0000085166.44904.79.

Pettey CM, McSweeney JC, Stewart KE. African Americans’ Perceptions of Adherence to Medications and Lifestyle Changes Prescribed to Treat Hypertension. Sage. 2016;6. https://doi.org/10.1177/2158244015623595

Ergul A: Hypertension in black patients: An emerging role of the endothelin system in salt-sensitive hypertension. Hypertension. 2000; 36: 62–67.

Victor RG, Leonard D, Hess P, Bhat DG, Jones J, Vaeth PAC, etal. Factors Associated With Hypertension Awareness, Treatment, and Control in Dallas County, Texas. Arch Intern Med. 2008;168(12):1285-1293. doi:10.1001/ archinte.168. 12.1285.

Medication Routines and Adherence Among Hypertensive African Americans Abida Solomon, PhD;1 Antoinette Schoenthaler, EdD;1,2 Azizi Seixas, PhD;2 Gbenga Ogedegbe, MD;2 Girardin Jean-Louis, PhD;2 Dejian Lai, PhD2

Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic Shock. Ann Intern Med. 1999;131:47-59.

Little WC,Applegate RJ. Congestive heart failure: systolic and diastolic function. J Cardiothorac Vasc Anesth. 1993;7(4):2-5.

Drazner MH. The Progression of Hypertensive Heart Disease. Circulation. 2011;123:327-334. https://doi.org/10.1161/CIRCULATIONAHA.108.845792.

Sánchez MA , Esteban MR, Pineda SO, Ortiz MR, Peña ER, Rubio DM, Belsué FV. Clinical Outcome and Reversibility of Systolic Dysfunction in Patients With Dilated Cardiomyopathy Due to Hypertension and Chronic Heart Failure. Rev Esp Cardiol. 2004;57:834-41 - Vol. 57 Num.09 DOI: 10.1016/S1885-5857(06)60648-8.

Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100:999–1008.

McMurray JV, McDonagh TA, Davie AP, et al. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J. 1998;19:842–846.

Moser M, Herbert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996; 27: 1214–1218.

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015; 2: 2. DOI: 10.17987/icfj.v2i1.4




DOI: https://doi.org/10.17987/icfj.v14i0.502

Copyright (c) 2019 Akinsanya Daniel Olusegun-Joseph, Kamilu M Karaye, Adeseye A Akintunde, Bolanle O Okunowo, Oladimeji G Opadijo, Suleiman A Balarabe, Abdulrazak Garba Habib

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.